AstraZeneca PLC (AZN)
Company Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines.
Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19.
The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia.
It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153.
The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
| Country | United Kingdom |
| Founded | 1992 |
| IPO Date | May 12, 1993 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 83,100 |
| CEO | Pascal Soriot |
Contact Details
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus Cambridge, X0 CB2 0AA United Kingdom | |
| Phone | 011 44 20 7304 5000 |
| Website | astrazeneca.com |
Stock Details
| Ticker Symbol | AZN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000901832 |
| CUSIP Number | 046353108 |
| ISIN Number | US0463531089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pascal Soriot D.V.M., M.B.A. | Chief Executive Officer and Executive Director |
| Dr. Aradhana Sarin M.D. | Chief Financial Officer and Executive Director |
| Marc Dunoyer | Chief Executive Officer of Alexion and Chief Strategy Officer |
| Pam P. Cheng | Executive Vice President of Operations and Information Technology and Member of External Sustainability Advisory Board |
| Chris Sheldon | Head of Investor Relations |
| Jeffrey Pott | Chief Human Resources Officer, General Counsel and Member of External Sustainability Advisory Board |
| Katarina Ageborg | Executive Vice President of Sustainability, Chief Compliance Officer and Member of External Sustainability Advisory Board |
| Gonzalo Vina | Head of Global Media Relations |
| Dr. Menelas Pangalos Ph.D. | Executive Vice President of BioPharmaceuticals Research & Development and Member of External Sustainability Advisory Board |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 22, 2023 | 6-K | Report of foreign issuer |
| Mar 22, 2023 | 6-K | Report of foreign issuer |
| Mar 15, 2023 | CERT | Certification by an exchange approving securities for listing |
| Mar 13, 2023 | 8-A12B | Registration of securities |
| Mar 9, 2023 | 6-K | Report of foreign issuer |
| Mar 8, 2023 | 6-K | Report of foreign issuer |
| Mar 8, 2023 | 6-K | Report of foreign issuer |
| Mar 6, 2023 | 6-K | Report of foreign issuer |
| Mar 3, 2023 | 6-K | Report of foreign issuer |
| Mar 2, 2023 | 424B2 | Prospectus |